ZOLEDRONIC ACID | N204016 | HOSPIRA INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 1 | Active | Mohammed Milhem | 17 | 2017-07-18 → 2028-05-01 | |
| Phase 3 | Active | UNICANCER | 318 | 2007-03 → 2026-12 | |
| Phase 2 | Active | University of Nebraska | 46 | 2016-09-16 → 2027-12 | |
| Phase 2/3 | Active | Medical Research Council | 11,992 | 2005-07-08 → 2030-12 | |
| Phase 1 | Recruiting | University of Wisconsin, Madison | 22 | 2016-02-12 → 2027-12 | |
| Phase 3 | Recruiting | St. Louis University | 120 | 2018-05-03 → 2028-01 | |
| Phase 4 | Completed | Aarhus University Hospital | 61 | 2017-03-13 → 2020-08-01 | |
| Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 54 | 2018-03-05 → 2023-07-25 | |
| Phase 2 | Completed | Northwestern University | 60 | 2015-02 → 2020-08-25 | |
| Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 439 | 2001-12 → 2009-02 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
19 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Dec 21, 2018 | SUPPL -3 | View Letter (PDF) |
| Dec 30, 2015 | ORIG -1 | View Letter (PDF) |
| Jul 8, 2013 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.